On October 5, 2021, NanoView Biosciences announced the release of the ExoView R200, its next-generation platform for the sensitive detection and characterization of extracellular vesicles (EVs), including exosomes, and also viral vectors. Launched in 2019, ExoView provides high-resolution sizing, counting, and phenotyping of exosomes and viral vectors at the individual EV level. Understanding the biomarkers carried by EVs has potential for diagnostic, prognostic, and therapeutic use for a broad range of diseases. The company says that the original ExoView R100 platform revolutionized EV detection, delivering EV sizing down to 50 nm, with high sensitivity and specificity that cannot be matched by existing EV characterization. The ExoView platform also requires low sample input, no extensive sample preparation or purification, and minimal hands-on time.
Login Or Register To Read Full Story